Sponsor Pipeline

University College, London Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
157
Active Trials
71
Recruiting
18
Phase 3
10
Disease Areas
14
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-08-13 NCT05777499
MUSic Therapy In Complex Specialist Neurorehabilitation
Trial completed
2026-08-13 NCT05777499
MUSic Therapy In Complex Specialist Neurorehabilitation
date change Primary completion pushed: 2025-06 -> 2026-02-01
2026-08-13 NCT05777499
MUSic Therapy In Complex Specialist Neurorehabilitation
date change Completion pushed: 2025-10 -> 2026-02-28
2026-08-12 NCT05544526
CAR T Cells to Target GD2 for DMG
date change Primary completion pushed: 2025-12 -> 2027-08
2026-08-12 NCT05544526
CAR T Cells to Target GD2 for DMG
date change Completion pushed: 2039-12 -> 2042-08
2026-08-12 NCT05391490
Allogeneic T Cells Expressing T Cell Receptor-KDEL and the Chimeric Antigen Receptor…
Recruitment opened
2026-08-12 NCT05391490
Allogeneic T Cells Expressing T Cell Receptor-KDEL and the Chimeric Antigen Receptor…
date change Primary completion pushed: 2024-11 -> 2027-02
2026-08-12 NCT05391490
Allogeneic T Cells Expressing T Cell Receptor-KDEL and the Chimeric Antigen Receptor…
date change Completion pushed: 2034-11 -> 2040-02
2026-08-09 NCT05361135
18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus…
overall status: Not Yet Recruiting → Unknown
2026-08-05 NCT07549893
Middle Meningeal Artery Coagulation During Burr-Hole Drainage for Chronic Subdural…
Recruitment opened
2026-08-05 NCT06778122
In-Bedroom Renewed Air as Anti-inflammatory Adjuvant Therapy in Cancer Survivors
Trial completed
2026-08-05 NCT06778122
In-Bedroom Renewed Air as Anti-inflammatory Adjuvant Therapy in Cancer Survivors
date change Primary completion moved earlier: 2026-07-31 -> 2026-06-19
2026-07-30 NCT07135271
BeSpoke Decision Support for Patients With Newly Diagnosed Localised Prostate Cancer
Recruitment opened
2026-07-24 NCT07717632
AI-enhanced LF-MRI in Epilepsy
Primary endpoint(s) modified
New Trial Filings, Last 30 Days
First PostedTrialPhaseStatus
2026-08-07 NCT07751133 Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer Phase 3 Not Yet Recruiting
2026-08-07 NCT07751380 Multi-modular Chimeric Antigen Receptor T Cells tarGeting B7-H3 in Children, Teenage &… Phase 1 Recruiting
2026-07-24 NCT07726693 Apixaban to Prevent Decompensation of Early Liver Cirrhosis Trial Phase 3 Not Yet Recruiting
2026-07-23 NCT07724132 An Evaluation of Treatments for Sustained Clinical Response (18 Months) in Symptomatic… Phase 3 Recruiting
2026-07-21 NCT07717632 AI-enhanced LF-MRI in Epilepsy Active, Not Recruiting
Active Trials by Phase
Phase 3
16
Phase 2/3
2
Phase 2
19
Phase 1/2
5
Phase 1
12
Early Phase 1
1
Not specified
102
Active Trials — top 25 of 157
NCT IDTitleConditionStatus
Phase 3
NCT03288532 Renal Adjuvant MultiPle Arm Randomised Trial Renal Cell Carcinoma Recruiting
NCT05405868 Nicotinamide in Glaucoma (NAMinG): A Randomised, Placebo-controlled, Multi-centre, Phase… Glaucoma, Open-Angle Recruiting
NCT05778617 Ambroxol to Slow Progression in Parkinson Disease Parkinson Disease Recruiting
NCT06320067 A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive… Prostate Cancer Metastatic Recruiting
NCT07207057 Edmond J. Safra Accelerating Clinical Trials in Parkinson's Disease: A Multiarm… Parkinsons Disease (PD) Recruiting
NCT04685616 Brentuximab Vedotin in Early Stage Hodgkin Lymphoma Hodgkin Lymphoma Recruiting
NCT07724132 An Evaluation of Treatments for Sustained Clinical Response (18 Months) in Symptomatic… Alzheimer's Disease (AD) Recruiting
NCT02544308 Trial of Immunomodulatory Therapy in High Risk Solitary Bone Plasmacytoma Plasmacytoma Active, Not Recruiting
NCT00943423 PET Scan in Planning Treatment in Patients Undergoing Combination Chemotherapy For Stage… Lymphoma Active, Not Recruiting
NCT06242782 Vertical Ridge Augmentation Strategies Alveolar Bone Resorption Not Yet Recruiting
NCT01566240 Induction Chemotherapy Plus Chemoradiation as First Line Treatment for Locally Advanced… Cervical Cancer Active, Not Recruiting
NCT05073835 Semaglutide 2.4 mg in Patients With Poor Weight-loss Obesity Active, Not Recruiting
NCT02804815 Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival… Cancer Active, Not Recruiting
NCT07163143 Optimal Treatment Duration for Radiographically Apparent, Bacteriologically Unconfirmed… Tuberculosis (TB) Not Yet Recruiting
NCT07726693 Apixaban to Prevent Decompensation of Early Liver Cirrhosis Trial Liver Cirrhosis Not Yet Recruiting
NCT07751133 Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer Prostate Cancer Not Yet Recruiting
Phase 2/3
NCT04061512 Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC)… Waldenstrom Macroglobulinemia Recruiting
NCT01398085 IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer… Thyroid Cancer Active, Not Recruiting
Phase 2
NCT05080556 Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive… Ovarian Cancer Recruiting
NCT05185739 Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC) Hepatocellular Carcinoma Recruiting
NCT06071871 A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell… Large B-cell Lymphoma Recruiting
NCT05635162 Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma Mantle Cell Lymphoma Recruiting
NCT06762769 Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma Smouldering Myeloma Recruiting
NCT06114628 Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB Pulmonary Tuberculosis Recruiting
NCT05197322 NEOadjuvant PembRolizumab In Stratified Medicine - ColoRectal Cancer Adenocarcinoma of the Colon Recruiting
See all 157 active University College, London trials with filters →
Disease Areas
Get alerts when University College, London's trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free